Moteur de recherche d’entreprises européennes
Financement de l’UE (8 603 990 €) : Développement clinique précoce d’un vaccin combiné vivant atténué contre la diarrhée Shigella et ETEC Hor14/06/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Développement clinique précoce d’un vaccin combiné vivant atténué contre la diarrhée Shigella et ETEC
Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.
| EUROPEAN VACCINE INITIATIVE e. V. | 359 755 € |
| Eveliqure Biotechnologies GmbH | 5 024 402 € |
| Goeteborgs Universitet | 749 843 € |
| 1 924 713 € | |
| Path | 545 278 € |
https://cordis.europa.eu/project/id/815568
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "EUROPEAN VACCINE INITIATIVE e. V. - Financement de l’UE (8 603 990 €) : Développement clinique précoce d’un vaccin combiné vivant atténué contre la diarrhée Shigella et ETEC"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
